glp-1 receptor agonist dry eye Unlocking the potential of agonists in ocular therapeutics: from molecular pathways to clinical impact GLP-1 Drug Alleviates Age-Related Dry
Description
doi: 10.1038/s41467-024-49655-6
Healthcare policy discussions continue regarding potential modification of statutory insurance restrictions to include evidence-based obesity pharmacotherapy
For short-acting, daily administered GLP-1RAs, cessation on the day of surgery is advised
Insulin resistance in T1D could also be related to the insulin administration route
W.HungC
The 2025 Standards of Medical Care in Diabetes ADA guidelines designate using GLP-1 RA with or without SGLT2i in patients with T2DM and ASCVD in preventing MACE [54]
